Efficacy and safety of rituximab in the treatment of primary central nervous system lymphoma: A meta-analysis and systematic review of 1,388 patients. (PubMed, Oncol Lett) - Sep 16, 2026 - "In conclusion, based on this meta-analysis, rituximab significantly improved the prognosis of patients with PCNSL without a significant difference in safety compared to the existing treatment regimens. Further high-quality randomized controlled trials are warranted to confirm these findings."
Journal • Retrospective data • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Central Nervous System Lymphoma
|
|
Chunxing Li; Dongxiao Wang; Lichaoyue Sun; Qing Xie; Wei Chen; Wenshu Li; Zhao Ren
|